BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34359076)

  • 1. Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia.
    Messling JE; Agger K; Andersen KL; Kromer K; Kuepper HM; Lund AH; Helin K
    Blood; 2022 Jan; 139(2):245-255. PubMed ID: 34359076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting leukemia-specific dependence on the de novo purine synthesis pathway.
    Yamauchi T; Miyawaki K; Semba Y; Takahashi M; Izumi Y; Nogami J; Nakao F; Sugio T; Sasaki K; Pinello L; Bauer DE; Bamba T; Akashi K; Maeda T
    Leukemia; 2022 Feb; 36(2):383-393. PubMed ID: 34344987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
    Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
    Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
    Nakatani K; Matsuo H; Harata Y; Higashitani M; Koyama A; Noura M; Nishinaka-Arai Y; Kamikubo Y; Adachi S
    Int J Hematol; 2021 Feb; 113(2):243-253. PubMed ID: 33068248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines.
    Katayama K; Nishihata A
    Biol Pharm Bull; 2021 Dec; 44(12):1843-1850. PubMed ID: 34602526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
    Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
    Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
    Heo SK; Noh EK; Kim JY; Jeong YK; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Sci Rep; 2017 Nov; 7(1):15278. PubMed ID: 29127384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.
    Liang H; Zheng QL; Fang P; Zhang J; Zhang T; Liu W; Guo M; Robinson CL; Chen SB; Chen XP; Chen FP; Zeng H
    Sci Rep; 2017 Jan; 7():40361. PubMed ID: 28098170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
    Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
    Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
    Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
    Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
    Xu L; Zhang Y; Gao M; Wang G; Fu Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
    Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
    PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.